CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 375 enrolled
Drug / intervention
Semaglutide +1 moredrug
Likely dose
Semaglutide 2.4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04251156
NCT04251156Phase 3Completed

Effect and Safety of Semaglutide 2.4 mg Once-weekly on Weight Management in Subjects With Overweight or Obesity.

Novo Nordisk A/S·interventional·Posted Jan 31, 2020·Updated Jan 29, 2026

In Brief

A Phase 3 clinical trial evaluating Semaglutide and Placebo (semaglutide) for Overweight and 2 related conditions. Completed, enrolled 375 participants across 33 sites in 4 countries.

Detailed Summary

This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine participants will have talks with study staff about healthy food choices, how to be more physically active and what else they can do to lose weight. Participants will either get semaglutide or "dummy medicine" - which treatment is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skinfold in the stomach, thigh or upper arm.• The study will last for about 1 year. Participants will have 11 clinic visits and 8 phone calls with the study doctor. Participants will have 3 clinic visits where they cannot eat and drink (water is allowed) for up to 8 hours before the visit and 1 clinic visit where they cannot eat and drink for up to 2 hours before the visit. (4 visits and 1 visit, respectively, if they have type 2 diabetes (T2D)). Participants will have 4 clinic visits where they will have blood samples taken. (5 visits if they have T2D). For China: Participants will have 9 clinic visits where they will have blood samples taken. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBrazil, China, Hong Kong, South Korea
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedJan 31, 2020
Enrollment StartDec 8, 2020
Primary CompletionAug 23, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.4 years ago

Interventions

Semaglutidedrug

Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg

Placebo (semaglutide)drug

Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks